ACROMEGALIC CARDIOMYOPATHY IN AN OLDER ADULT: A CASE REPORT AND A REVIEW OF DIAGNOSTIC AND THERAPEUTIC APPROACHES

Dung Tran Vo Tri 1 , , Tạ Hoàng Lưu 1 , Nguyễn Quốc Phòng 1 , Nguyễn Thị Kim Ngọc 1 , Trần Trung Kiên 2 , Nguyễn Thanh Vy 1, 2 , Nguyễn Thị Mai Hương 2 , Nguyễn Thanh Huân 1, 2
1 University of Medicine and Pharmacy at Ho Chi Minh City image/svg+xml
2 Thong Nhat Hospital image/svg+xml
* Corresponding author:

Article Information

Metrics
Downloads: 9 Views: 25
DOI
10.63947/bvtn.v2i6.20
Published
2026-02-27
Issue Vol. 2 No. 6 (2026): Thách thức trong lão khoa 2026: Những giải pháp điều trị và chăm sóc toàn diện
Section
Case Report
Categories
Research

Download Article

PDF (Vietnamese)

How to Cite

1.
Tran Vo Tri D, Hoàng Lưu T, Quốc Phòng N, Thị Kim Ngọc N, Trung Kiên T, Thanh Vy N, Thị Mai Hương N, Thanh Huân N. ACROMEGALIC CARDIOMYOPATHY IN AN OLDER ADULT: A CASE REPORT AND A REVIEW OF DIAGNOSTIC AND THERAPEUTIC APPROACHES. JHA [Internet]. Vietnam; 2026 Feb. 27 [cited 2026 Mar. 15];2(6):134–140. https://tcsuckhoelaohoa.vn/bvtn/article/view/148 doi: 10.63947/bvtn.v2i6.20
Loading citation...
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Acromegalic cardiomyopathy is classified as an endocrine cardiomyopathy. Acromegaly is characterized by the hypersecretion of Growth Hormone (GH) and its peripheral mediator, Insulin-like Growth Factor 1 (IGF-1). The etiology in the majority of cases is a pituitary adenoma. Chronic elevation of circulating GH and IGF-1 levels affects cardiomyocyte growth, myocardial contractility, and triggers various indirect mechanisms culminating in cardiomyopathy. The clinical phenotype typically presents as hypertrophic cardiomyopathy; however, without hormonal control, it may progress to a dilated cardiomyopathy phenotype with reduced ejection fraction. In this article, we report a clinical case in an older patient presenting with dyspnea. Based on clinical and diagnostic findings, the patient was diagnosed with acromegaly secondary to a pituitary adenoma, complicated by heart failure with reduced ejection fraction (HFrEF). Management included diuretics for decongestion and optimization of Guideline-Directed Medical Therapy (GDMT), with planned pituitary tumor resection upon stabilization of heart failure. However, the patient declined surgical intervention.

Keywords

cardiomyopathy acromegaly acromegalic cardiomyopathy

References

  1. Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. The Lancet Diabetes & Endocrinology. 2022;10(11):804-26. doi: 10.1016/S2213-8587(22)00244-3. DOI: https://doi.org/10.1016/S2213-8587(22)00244-3
  2. Sherin RPV, Vietor NO, Usman A, Hoang TD, Shakir MKM. Cardiovascular Disorders Associated With Acromegaly: an Update. Endocrine Practice. 2024;30(12):1212-9. doi: 10.1016/j.eprac.2024.09.014. DOI: https://doi.org/10.1016/j.eprac.2024.09.014
  3. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(37):3503-626. doi: 10.1093/eurheartj/ehad194. DOI: https://doi.org/10.1093/eurheartj/ehad194
  4. Colao A, Grasso LFS, Di Somma C, Pivonello R. Acromegaly and Heart Failure. Heart Failure Clinics. 2019;15(3):399-408. doi: 10.1016/j.hfc.2019.03.001. DOI: https://doi.org/10.1016/j.hfc.2019.03.001
  5. Iglesias P. Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact. Journal of Clinical Medicine. 14(6):[1906 p.]. DOI: https://doi.org/10.3390/jcm14061906
  6. Orihuela Rodríguez O, Valle Nava L, Ferreira-Hermosillo A, Carmona-Ruiz HA, Acevedo Meléndez A, Jacobo Ruvalcaba A, et al. Echocardiographic Findings in Cardiomyopathy Due to Acromegaly. Biomedicines. 13(3):[605 p.]. DOI: https://doi.org/10.3390/biomedicines13030605
  7. Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7-22. doi: 10.1007/s11102-023-01360-1. PubMed PMID: 37923946; PubMed Central PMCID: PMC10837217. DOI: https://doi.org/10.1007/s11102-023-01373-w
  8. Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A, et al. Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography. 2022;35(6):533-69. doi: 10.1016/j.echo.2022.03.012. DOI: https://doi.org/10.1016/j.echo.2022.03.012
  9. Guo X, Cao J, Liu P, Cao Y, Li X, Gao L, et al. Cardiac Abnormalities in Acromegaly Patients: A Cardiac Magnetic Resonance Study. International Journal of Endocrinology. 2020;2020(1):2018464. doi: https://doi.org/10.1155/2020/2018464. DOI: https://doi.org/10.1155/2020/2018464
  10. Ságová I, Bolek T, Dragula M, Péč MJ, Benko J, Jurica J, et al. Effects of Treatment on Structural and Functional Parameters of the Left Heart in Naïve Acromegaly Patients: Prospective Single-Centre Study: 12-Month Follow-Up. Journal of Clinical Medicine. 14(10):[3397 p.]. DOI: https://doi.org/10.3390/jcm14103397
  11. Melmed S, di Filippo L, Fleseriu M, Mercado M, Karavitaki N, Gurnell M, et al. Consensus on acromegaly therapeutic outcomes: an update. Nature Reviews Endocrinology. 2025;21(11):718-37. doi: 10.1038/s41574-025-01148-2. DOI: https://doi.org/10.1038/s41574-025-01148-2
  12. Gadelha MR, Wildemberg LE, Marques NV, Kasuki L. Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future. Endocrine Reviews. 2025;46(6):838-55. doi: 10.1210/endrev/bnaf020. DOI: https://doi.org/10.1210/endrev/bnaf020

License

© 2026 The Author(s). Published by Journal of Health and Aging.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.